Artemísia L Mourão1, Fabiana G de Abreu1, Marilu Fiegenbaum2,3. 1. Graduate Program in Biological Sciences and Rehabilitation, Methodist University Centre, IPA, Porto Alegre, RS, Brazil. 2. Graduate Program in Biological Sciences and Rehabilitation, Methodist University Centre, IPA, Porto Alegre, RS, Brazil. mariluf@ufcspa.edu.br. 3. Department of Basic Health Sciences, Federal Health Sciences University of Porto Alegre, Rua Sarmento Leite, 245/403, CEP 90050-170, Porto Alegre, RS, Brazil. mariluf@ufcspa.edu.br.
Abstract
BACKGROUND AND OBJECTIVES: Propofol is the most commonly used hypnotic worldwide, but its effective dose varies greatly between individuals. The present study sought to investigate the relationship between the c.516G>T polymorphism in the CYP2B6 (cytochrome P450 2B6) gene and the required propofol dose. METHODS: One hundred and eight patients treated with propofol were recruited, and environmental, clinical and surgical data were collected. Genotyping for the c.516G>T polymorphism was performed by real-time PCR. Multiple linear regression analysis was performed to estimate the predictive variables of the total propofol dose. RESULTS: For patients under general anaesthesia, the predictive variables of the total propofol dose were surgery duration (partial R (2) = 19.9 %), age (partial R (2) = 10.5 %), weight (partial R (2) = 10.1 %) and presence of the T allele (partial R (2) = 6.8 %). From the estimated coefficient of regression values, the surgery duration and weight were the factors that increased the propofol dose, while age and presence of the T allele decreased the total dose of the drug needed. The total propofol doses based on the GG or GT/TT genotypes were 151.5 ± 64.2 mg and 129.3 ± 44.6 mg, respectively (p = 0.043). CONCLUSIONS: Our results indicate that 34 % of the variance in the required propofol dose may be explained by these factors and that CYP2B6 c.516G>T polymorphism, which decreases the metabolism of the drug, accounts for approximately 7 % of the drug dosage. Our results show the possible influence of CYP2B6 c.516G>T genetic variant on propofol dose in patients under general anaesthesia.
BACKGROUND AND OBJECTIVES:Propofol is the most commonly used hypnotic worldwide, but its effective dose varies greatly between individuals. The present study sought to investigate the relationship between the c.516G>T polymorphism in the CYP2B6 (cytochrome P450 2B6) gene and the required propofol dose. METHODS: One hundred and eight patients treated with propofol were recruited, and environmental, clinical and surgical data were collected. Genotyping for the c.516G>T polymorphism was performed by real-time PCR. Multiple linear regression analysis was performed to estimate the predictive variables of the total propofol dose. RESULTS: For patients under general anaesthesia, the predictive variables of the total propofol dose were surgery duration (partial R (2) = 19.9 %), age (partial R (2) = 10.5 %), weight (partial R (2) = 10.1 %) and presence of the T allele (partial R (2) = 6.8 %). From the estimated coefficient of regression values, the surgery duration and weight were the factors that increased the propofol dose, while age and presence of the T allele decreased the total dose of the drug needed. The total propofol doses based on the GG or GT/TT genotypes were 151.5 ± 64.2 mg and 129.3 ± 44.6 mg, respectively (p = 0.043). CONCLUSIONS: Our results indicate that 34 % of the variance in the required propofol dose may be explained by these factors and that CYP2B6 c.516G>T polymorphism, which decreases the metabolism of the drug, accounts for approximately 7 % of the drug dosage. Our results show the possible influence of CYP2B6 c.516G>T genetic variant on propofol dose in patients under general anaesthesia.
Authors: Irena Loryan; Marja Lindqvist; Inger Johansson; Masahiro Hiratsuka; Ilse van der Heiden; Ron H N van Schaik; Jan Jakobsson; Magnus Ingelman-Sundberg Journal: Eur J Clin Pharmacol Date: 2011-10-18 Impact factor: 2.953
Authors: Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada Journal: Br J Clin Pharmacol Date: 2001-03 Impact factor: 4.335
Authors: Marco H Hofmann; Julia K Blievernicht; Kathrin Klein; Tanja Saussele; Elke Schaeffeler; Matthias Schwab; Ulrich M Zanger Journal: J Pharmacol Exp Ther Date: 2008-01-02 Impact factor: 4.030
Authors: Ellie H Jhun; Jeffrey L Apfelbaum; David M Dickerson; Sajid Shahul; Randall Knoebel; Keith Danahey; Mark J Ratain; Peter H O'Donnell Journal: Pharmacogenomics Date: 2019-07 Impact factor: 2.638
Authors: Dimitrije Pavlovic; Ivana Budic; Tatjana Jevtovic Stoimenov; Dragana Stokanovic; Vesna Marjanovic; Marija Stevic; Milan Slavkovic; Dusica Simic Journal: Pharmgenomics Pers Med Date: 2020-01-17
Authors: Rafael B R León-Cachón; Aileen-Diane Bamford; Irene Meester; Hugo Alberto Barrera-Saldaña; Magdalena Gómez-Silva; María F García Bustos Journal: Sci Rep Date: 2020-06-01 Impact factor: 4.379